Shareholding disclosure

Armistice Capital LLC

Declared position

4.9%

Threshold

Crossed upwards

Timeline

Published

12.04.2024

Transaction

03.04.2024

Voting rights breakdown

Voting rights acquired4.9%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000O9J6

Beneficial owner

Armistice Capital LLC

Declared address

Armistice Capital LLC, New York, NY, US

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Armistice Capital LLC

MindMaze Therapeutics Holding SA12.04.2024ZA01-000000000O9J6

Disclosure summary

Armistice Capital LLC disclosed a holding in MindMaze Therapeutics Holding SA on the acquisition side, published by SIX Exchange Regulation on 12.04.2024, at 4.9% of voting rights. Notice category: Single shareholder.

Disclosed position

4.9%

Voting rights acquired

Voting rights acquired4.9%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Armistice Capital LLC disclosed a holding in MindMaze Therapeutics Holding SA, published on 12.04.2024.

Publication date12.04.2024

Transaction date03.04.2024

Issuing companyMindMaze Therapeutics Holding SA

Beneficial ownerArmistice Capital LLC

Declared addressArmistice Capital LLC, New York, NY, US

CategorySingle shareholder

Voting rights acquired4.9%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000O9J6

Source: SIX Exchange Regulation · Publication date: 12.04.2024

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open